Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia

Clinical and biochemical effects of Gamma-vinyl-Gaba (GVG) have been evaluated in a blind video-controlled study in 10 psychiatric patients (mean age 71 yr) with tardive dyskinesia. CSF free and total Gaba and homocarnosine concentrations increased from three to five fold with GVG treatment. Despite...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 1987-12, Vol.50 (12), p.1674-1678
Main Authors: Gaio, J M, Pollak, P, Hommel, M, Perret, J
Format: Article
Language:English
Subjects:
Aged
Aminocaproates - adverse effects
Aminocaproates - therapeutic use
Biological and medical sciences
Carnosine - analogs & derivatives
Carnosine - cerebrospinal fluid
Dyskinesia, Drug-Induced - cerebrospinal fluid
Dyskinesia, Drug-Induced - drug therapy
Dyskinesia, Drug-Induced - physiopathology
gamma-Aminobutyric Acid - cerebrospinal fluid
Humans
Medical sciences
Mental Disorders - cerebrospinal fluid
Mental Disorders - physiopathology
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Vigabatrin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical and biochemical effects of Gamma-vinyl-Gaba (GVG) have been evaluated in a blind video-controlled study in 10 psychiatric patients (mean age 71 yr) with tardive dyskinesia. CSF free and total Gaba and homocarnosine concentrations increased from three to five fold with GVG treatment. Despite the GVG-induced biological effects on Gaba metabolism, GVG did not consistently improve tardive dyskinesia. Psychomotor side-effects occurred in older patients, who only tolerated GVG dosages of 2-4 g/day.
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp.50.12.1674